India · Delayed Price · Currency is INR Beryl Drugs Statistics
Total Valuation
Beryl Drugs has a market cap or net worth of INR 116.14 million. The enterprise value is 137.81 million.
| Market Cap | 116.14M |
| Enterprise Value | 137.81M |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Beryl Drugs has 5.07 million shares outstanding. The number of shares has decreased by -0.29% in one year.
| Current Share Class | 5.07M |
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | -0.29% |
| Shares Change (QoQ) | -3.02% |
| Owned by Insiders (%) | 41.60% |
| Owned by Institutions (%) | n/a |
| Float | 2.96M |
Valuation Ratios
The trailing PE ratio is 27.26.
| PE Ratio | 27.26 |
| Forward PE | n/a |
| PS Ratio | 0.62 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 3.18 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 32.44 |
| EV / Sales | 0.73 |
| EV / EBITDA | 5.68 |
| EV / EBIT | 14.78 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.52 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.01 |
| Debt / FCF | -13.97 |
| Interest Coverage | 2.71 |
Financial Efficiency
Return on equity (ROE) is 4.38% and return on invested capital (ROIC) is 5.23%.
| Return on Equity (ROE) | 4.38% |
| Return on Assets (ROA) | 3.77% |
| Return on Invested Capital (ROIC) | 5.23% |
| Return on Capital Employed (ROCE) | 8.89% |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.22 |
| Inventory Turnover | 3.63 |
Taxes
In the past 12 months, Beryl Drugs has paid 1.63 million in taxes.
| Income Tax | 1.63M |
| Effective Tax Rate | 27.76% |
Stock Price Statistics
The stock price has increased by +17.44% in the last 52 weeks. The beta is -0.00, so Beryl Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.00 |
| 52-Week Price Change | +17.44% |
| 50-Day Moving Average | 22.20 |
| 200-Day Moving Average | 22.41 |
| Relative Strength Index (RSI) | 58.62 |
| Average Volume (20 Days) | 2,375 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Beryl Drugs had revenue of INR 188.20 million and earned 4.25 million in profits. Earnings per share was 0.84.
| Revenue | 188.20M |
| Gross Profit | 90.54M |
| Operating Income | 9.32M |
| Pretax Income | 5.88M |
| Net Income | 4.25M |
| EBITDA | 24.26M |
| EBIT | 9.32M |
| Earnings Per Share (EPS) | 0.84 |
Balance Sheet
The company has 2.74 million in cash and 24.41 million in debt, with a net cash position of -21.67 million or -4.27 per share.
| Cash & Cash Equivalents | 2.74M |
| Total Debt | 24.41M |
| Net Cash | -21.67M |
| Net Cash Per Share | -4.27 |
| Equity (Book Value) | 98.88M |
| Book Value Per Share | 19.51 |
| Working Capital | 23.49M |
Cash Flow
In the last 12 months, operating cash flow was 36.50 million and capital expenditures -38.24 million, giving a free cash flow of -1.75 million.
| Operating Cash Flow | 36.50M |
| Capital Expenditures | -38.24M |
| Depreciation & Amortization | 14.93M |
| Net Borrowing | -16.83M |
| Free Cash Flow | -1.75M |
| FCF Per Share | -0.34 |
Margins
Gross margin is 48.11%, with operating and profit margins of 4.95% and 2.26%.
| Gross Margin | 48.11% |
| Operating Margin | 4.95% |
| Pretax Margin | 3.12% |
| Profit Margin | 2.26% |
| EBITDA Margin | 12.89% |
| EBIT Margin | 4.95% |
| FCF Margin | n/a |
Dividends & Yields
Beryl Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.29% |
| Shareholder Yield | 0.29% |
| Earnings Yield | 3.66% |
| FCF Yield | -1.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |